Efficacy and Safety of Tunlametinib in Adults with Inoperable Neurofibromatosis Type 1–Associated Plexiform Neurofibromas: Phase IIa Trial and Biomarker Research

20260 citationsJournal Article

Authors

Zhichao Wang · Shanghai Ninth People's Hospital

Jingxuan Huang · Shanghai Ninth People's Hospital

Jun Liu · Shanghai Ninth People's Hospital

Yuehua Li · Shanghai Ninth People's Hospital

Wei Chen · Shanghai Ninth People's Hospital

Yihui Gu · Shanghai Ninth People's Hospital

Ying Cheng

Abstract

Tunlametinib demonstrated promising efficacy and an acceptable safety profile in adults with PN, broadly aligning with prior PN trial including selumetinib and mirdametinib.

Topics & Keywords

Neurofibromatosis and Schwannoma Cases Tuberous Sclerosis Complex Research Myasthenia Gravis and Thymoma

Publication Details

Published in: Clinical Cancer Research

DOI: 10.1158/1078-0432.ccr-25-3291

Field-Weighted Citation Impact: 0.00

Command Palette

Efficacy and Safety of Tunlametinib in Adults with Inoperable Neurofibromatosis Type 1–Associated Plexiform Neurofibromas: Phase IIa Trial and Biomarker Research

Authors

Abstract

Topics & Keywords

Publication Details